SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?


To: Freedom Fighter who wrote (75432)2/8/2000 6:19:00 PM
From: Knighty Tin  Read Replies (1) | Respond to of 132070
 
Wayne, With great difficulty and subjectivity. I look at the pipeline as it currently exists and figure the cash flow for each product if it leads in that indication, if it is just one of the pack, and if it is a laggard. Then, I discount that number by both the time involved and by a failure factor.

So, it is a lot like valuing internut stocks. If you have perfect inputs, you are in good shape. And if you have them, tell me where you got them. <g>

Last year, most of the smaller biotech stocks were undervalued if even one product became a laggard. Today, most are fairly valued if one product goes on to become the leader for the indication.



To: Freedom Fighter who wrote (75432)2/9/2000 10:38:00 AM
From: Don Lloyd  Read Replies (2) | Respond to of 132070
 
Wayne -

Do you know, or have a url, that specifies exactly how the S&P500 is calculated?

TIA, Don